Peter Welford
Stock Analyst
(n/a)
# 4,652
Out of 4,654 analysts
13
Total ratings
n/a
Success rate
n/a
Average return
Main Sectors:
Top Industries:
Stocks Rated by Peter Welford
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GSK GSK | Downgrades: Hold | n/a | $33.35 | - | 3 | Nov 12, 2024 | |
| NVS Novartis AG | Downgrades: Hold | n/a | $103.06 | - | 2 | Sep 3, 2024 | |
| AZN AstraZeneca | Downgrades: Hold | n/a | $63.23 | - | 4 | Jan 3, 2024 | |
| GLPG Galapagos NV | Upgrades: Hold | $49 → $47 | $26.80 | +76.12% | 3 | Jan 23, 2023 | |
| GMAB Genmab | Downgrades: Hold | n/a | $20.59 | - | 1 | Sep 16, 2021 |
GSK
Nov 12, 2024
Downgrades: Hold
Price Target: n/a
Current: $33.35
Upside: -
Novartis AG
Sep 3, 2024
Downgrades: Hold
Price Target: n/a
Current: $103.06
Upside: -
AstraZeneca
Jan 3, 2024
Downgrades: Hold
Price Target: n/a
Current: $63.23
Upside: -
Galapagos NV
Jan 23, 2023
Upgrades: Hold
Price Target: $49 → $47
Current: $26.80
Upside: +76.12%
Genmab
Sep 16, 2021
Downgrades: Hold
Price Target: n/a
Current: $20.59
Upside: -